ContraVir Pharmaceuticals Inc. (CTRV) financial statements (2021 and earlier)

Company profile

Business Address 399 THORNALL STREET
EDISON, NJ 08837
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4114313752
Cash and cash equivalents4114313752
Prepaid expense2000010
Total current assets:4314313852
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment0000000
Intangible assets, net (including goodwill)55555 
Goodwill22222  
Intangible assets, net (excluding goodwill)33333  
Other undisclosed noncurrent assets0000000
Total noncurrent assets:6655500
TOTAL ASSETS:49208181352
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4113520
Accounts payable4012410
Accrued liabilities1011100
Debt 01 0  
Due to related parties      0
Other undisclosed current liabilities0      
Total current liabilities:5133520
Noncurrent Liabilities
Long-term debt and lease obligation01     
Long-term debt, excluding current maturities0      
Operating lease, liability01
Liabilities, other than long-term debt32367 4
Deferred revenue and credits0    
Deferred tax liabilities, net011  
Deferred income tax liabilities00
Business combination, contingent consideration, liability32333 
Derivative instruments and hedges, liabilities00022 4
Total noncurrent liabilities:33367 4
Total liabilities:84691225
Stockholders' equity
Stockholders' equity attributable to parent, including:41162913(3)
Common stock0000000
Additional paid in capital14398776832172
Accumulated deficit(104)(83)(76)(60)(45)(28)(5)
Other undisclosed stockholders' equity attributable to parent22211414 
Total stockholders' equity:41162913(3)
TOTAL LIABILITIES AND EQUITY:49208181352

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Operating expenses(20)(8)(15)(21)(21)(14)(2)
Operating loss:(20)(8)(15)(21)(21)(14)(2)
Nonoperating income (expense)   44(0)(4)
Interest and debt expense(0)(1)(0)   (0)
Loss from continuing operations before equity method investments, income taxes:(20)(8)(15)(17)(17)(14)(5)
Other undisclosed income (loss) from continuing operations before income taxes(0)05    
Loss from continuing operations before income taxes:(20)(8)(10)(17)(17)(14)(5)
Income tax expense (benefit)(0)112   
Net loss attributable to parent:(20)(7)(9)(15)(17)(14)(5)
Preferred stock dividends and other adjustments     (8) 
Other undisclosed net income (loss) available to common stockholders, basic(0)(5)(8)   0
Net loss available to common stockholders, basic:(20)(12)(18)(15)(17)(22)(5)
Other undisclosed net loss available to common stockholders, diluted   (3)   
Net loss available to common stockholders, diluted:(20)(12)(18)(18)(17)(22)(5)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
Net loss:(20)(7)(9)(15)(17)(14)(5)
Comprehensive loss, net of tax, attributable to parent:(20)(7)(9)(15)(17)(14)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: